Le cancer de la prostate métastatique sensible aux hormones répond aux critères de volume élevé...

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

ID	`RF-CHAARTED-HIGH-VOLUME-MHSPC`
Type	Signal d’alerte
État	reviewed 2026-04-27 \| pending_clinical_signoff
Maladies	`DIS-PROSTATE`
Sources	`SRC-EAU-PROSTATE-2024` `SRC-ESMO-PROSTATE-2024` `SRC-NCCN-PROSTATE-2025`

Origine du drapeau rouge

Définition	Metastatic hormone-sensitive prostate cancer meeting CHAARTED high-volume criteria — visceral metastases OR ≥4 bone metastases with at least 1 outside vertebral column / pelvis — supports docetaxel + ADT triplet (with or without darolutamide / abiraterone)
Direction clinique	intensifier
Catégorie	score de risque
Algorithme de décalage	ALGO-PROSTATE-MHSPC-1L

Logique de déclenchement

{
  "any_of": [
    {
      "finding": "prostate_chaarted_volume",
      "value": "high"
    },
    {
      "finding": "visceral_metastases_present",
      "value": true
    },
    {
      "all_of": [
        {
          "comparator": ">=",
          "finding": "bone_metastases_count",
          "threshold": 4
        },
        {
          "finding": "bone_metastases_outside_axial",
          "value": true
        }
      ]
    }
  ],
  "type": "composite_clinical"
}

Notes

CHAARTED (Sweeney NEJM 2015) defined high-volume as visceral mets OR ≥4 bone mets with ≥1 outside vertebrae and pelvis. High-volume cohort showed 17-mo OS improvement with docetaxel + ADT vs ADT alone (HR 0.60). ARASENS (Smith 2022) extended to triplet darolutamide + docetaxel + ADT with further OS benefit (HR 0.68 for OS) — high-volume preferred for triplet. PEACE-1 (Fizazi 2022) showed similar for abiraterone + docetaxel + ADT. Direction `intensify` toward triplet over doublet ADT+ARSI alone in CHAARTED high-volume. Co-fires with RF-LATITUDE-HIGH-RISK-MHSPC for LATITUDE high-risk overlap; triplet preferred when both fire.

Utilisé par

Algorithmes

ALGO-PROSTATE-MHSPC-1L - ALGO-PROSTATE-MHSPC-1L

Signal d’alerte

RF-LATITUDE-HIGH-RISK-MHSPC - Cancer de la prostate métastatique sensible aux hormones répondant aux critères de risque élevé LATITUDE — ≥2 de...